Drug targets for corona virus: A systematic review
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
century. However, the lack of specific drugs to prevent/treat an attack is a major need at this current point of time. In this regard, we conducted a systematic review to identify major druggable targets in coronavirus (CoV). We searched PubMed and RCSB database with keywords HCoV, NCoV, corona virus, SERS-CoV, MERS-CoV, 2019-nCoV, crystal structure, X-ray crystallography structure, NMR structure, target, and drug target till Feb 3, 2020. The search identified seven major targets (spike protein, envelop protein, membrane protein, protease, nucleocapsid protein, hemagglutinin esterase, and helicase) for which drug design can be considered. There are other 16 nonstructural proteins (NSPs), which can also be considered from the drug design perspective. The major structural proteins and NSPs may serve an important role from drug design perspectives. However, the occurrence of frequent recombination events is a major deterrent factor toward the development of CoV-specific vaccines/drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510 · cited 2×
“[23] These mature virions form a vesicle, which fuses with the plasma membrane and releases the virus particles into the extracellular region.[23,24] The detailed structure of CoV and its life cycle is depicted in Figures 1 and 2.”
BackgroundStructure, Function, and Evolution of Coronavirus Spike Proteins
Li, F. (2016) · Annual Review of Virology · doi:10.1146/annurev-virology-110615-042301 · Cited by 2,740
Coronavirus Infections—More Than Just the Common Cold
Paules, C. I., Marston, H. D., & Fauci, A. S. (2020) · JAMA · doi:10.1001/jama.2020.0757 · Cited by 2,136
Coronavirus envelope protein: current knowledge
Schoeman, D., & Fielding, B. C. (2019) · Virology Journal · doi:10.1186/s12985-019-1182-0 · Cited by 2,074
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
Belouzard, S., Millet, J. K., Licitra, B. N., & Whittaker, G. R. (2012) · Viruses · doi:10.3390/v4061011 · Cited by 1,368
Ding, Y., He, L., Zhang, Q., Huang, Z., Che, X., Hou, J., Wang, H., Shen, H., Qiu, L., Li, Z., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1560 · Cited by 1,076
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
Simmons, G., Gosalia, D. N., Rennekamp, A. J., Reeves, J. D., Diamond, S. L., & Bates, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505577102 · Cited by 1,052
Cited by
Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review
Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082690 · Cited by 822
Yoshimoto, F. K. (2020) · The Protein Journal · doi:10.1007/s10930-020-09901-4 · Cited by 543
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
Gasmi, A., Noor, S., Tippairote, T., Dadar, M., Menzel, A., & Bjørklund, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108409 · Cited by 305
Hasan, A., Paray, B. A., Hussain, A., Qadir, F. A., Attar, F., Aziz, F. M., Sharifi, M., Derakhshankhah, H., Rasti, B., Mehrabi, M., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1754293 · Cited by 293
“Given the high incidence of CoV resistance, especially in immunocompromised patients, the design of new drugs that target specific activities of the virus and stop one or more stages of its infection cycle is essential (Prajapat et al., 2020; Yang et al., 2020; Zhou & Zhao, 2020) .”
BackgroundAl-Karmalawy, A. A., Dahab, M. A., Metwaly, A. M., Elhady, S. S., Elkaeed, E. B., Eissa, I. H., & Darwish, K. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.661230 · Cited by 286
SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review
Narang, K., Enninga, E. A. L., Gunaratne, M. D. S. K., Ibirogba, E. R., Trad, A. T. A., Elrefaei, A., Theiler, R. N., Ruano, R., Szymanski, L. M., Chakraborty, R., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.05.011 · Cited by 279
Mhatre, S., Srivastava, T., Naik, S., & Patravale, V. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153286 · Cited by 263
Ashary, N., Bhide, A., Chakraborty, P., Colaco, S., Mishra, A., Chhabria, K., Jolly, M. K., & Modi, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00783 · Cited by 121
Kushwaha, P. P., Singh, A. K., Prajapati, K. S., Shuaib, M., Gupta, S., & Kumar, S. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104954 · Cited by 53
Self-citation
Metadata
- Authors
- Medhi, B., Prajapat#, M., Sarma#, P., Shekhar#, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., & Bansal, S.
- Venue
- Indian Journal of Pharmacology
- Publisher
- Medknow
- Published
- 2020
- Volume
- 52
- Issue
- 1
- Pages
- 56
- ISSN
- 0253-7613 (ISSN-L)
- OpenAlex
- W3012352458
- Cited by
- 496
- References
- 78
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.